Boston Scientific Corporation  

(Public, NYSE:BSX)   Watch this stock  
Find more results for bsx
24.48
-0.68 (-2.70%)
After Hours: 24.45 -0.03 (-0.12%)
Feb 23, 4:24PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 23.29 - 24.63
52 week 16.82 - 25.65
Open 23.37
Vol / Avg. 0.00/8.90M
Mkt cap 33.18B
P/E 97.02
Div/yield     -
EPS 0.25
Shares 1.36B
Beta 1.06
Inst. own 94%
Feb 2, 2017
Q4 2016 Boston Scientific Corp Earnings Release
Feb 2, 2017
Q4 2016 Boston Scientific Corp Earnings Call
Jan 10, 2017
Boston Scientific Corp at JPMorgan Healthcare Conference - Q&A Session
Jan 10, 2017
Boston Scientific Corp at JPMorgan Healthcare Conference
Dec 7, 2016
Boston Scientific Corp at Citi Global Healthcare Conference - Webcast
Nov 29, 2016
Boston Scientific Corp at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 5.66% 4.14%
Operating margin 6.39% 5.33%
EBITD margin - 22.43%
Return on average assets 2.78% 1.92%
Return on average equity 7.53% 5.32%
Employees 25,000 -
CDP Score - 58 E

Address

300 BOSTON SCIENTIFIC WAY
MARLBOROUGH, MA 01752-1234
United States - Map
+1-508-6834000 (Phone)
+1-508-6508923 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters.

Officers and directors

Michael F. Mahoney Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Joseph M. Fitzgerald Executive Vice President and President - Rhythm Management
Age: 52
Bio & Compensation  - Reuters
Daniel J. Brennan Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Timothy A. Pratt Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
Age: 66
Bio & Compensation  - Reuters
Supratim Bose Executive Vice President and President - Asia-Pacific, Middle East and Africa
Age: 63
Bio & Compensation  - Reuters
Keith D. Dawkins M.D. Global Chief Medical Officer, Executive Vice President
Age: 65
Bio & Compensation  - Reuters
Edward F. Mackey Executive Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Michael P. Phalen Executive Vice President and President - MedSurg
Age: 56
Bio & Compensation  - Reuters
Wendy Carruthers Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Kevin J. Ballinger Senior Vice President and President - Interventional Cardiology
Age: 43
Bio & Compensation  - Reuters